As of Jan 13
| -0.29 / -0.40%|
The 22 analysts offering 12-month price forecasts for Gilead Sciences have a median target of 95.50, with a high estimate of 118.00 and a low estimate of 81.00. The median estimate represents a +30.70% increase from the last price of 73.07.
The current consensus among 30 polled investment analysts is to Buy stock in Gilead Sciences. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.